公开(公告)号：US09868704B2

公开(公告)日：2018-01-16

申请号：US15186246

申请日：2016-06-17

Applicant: GENENTECH, INC.

Inventor： Nicholas D. Smith ,  Mehmet Kahraman ,  Steven P. Govek ,  Johnny Y. Nagasawa ,  Andiliy G. Lai ,  Jackaline D. Julien ,  Mark R. Herbert ,  Karensa L. Douglas

IPC: C07D231/56 ,  A61K31/416 ,  C07D209/08 ,  C07D249/18 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7105 ,  C07D215/227 ,  C07D217/24 ,  C07D265/18 ,  C07D277/68 ,  C07D279/16 ,  C07D401/10 ,  C07D409/10 ,  C07D471/04 ,  C07D495/04 ,  C07D401/12 ,  C07D403/10 ,  C07D413/10 ,  C07D417/10 ,  C07C215/10

CPC classification number: C07D231/56 ,  A61K31/416 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7105 ,  C07C215/10 ,  C07D209/08 ,  C07D215/227 ,  C07D217/24 ,  C07D249/18 ,  C07D265/18 ,  C07D277/68 ,  C07D279/16 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20160297767A1

公开(公告)日：2016-10-13

申请号：US15186246

申请日：2016-06-17

Applicant: GENENTECH, INC.

Inventor： Nicholas D. Smith ,  Mehmet Kahraman ,  Steven P. Govek ,  Johnny Y. Nagasawa ,  Andiliy G. Lai ,  Jackaline D. Julien ,  Mark R. Herbert ,  Celine Bonnefous ,  Karensa L. Douglas

IPC: C07D231/56 ,  C07C215/10

CPC classification number: C07D231/56 ,  A61K31/416 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7105 ,  C07C215/10 ,  C07D209/08 ,  C07D215/227 ,  C07D217/24 ,  C07D249/18 ,  C07D265/18 ,  C07D277/68 ,  C07D279/16 ,  C07D401/10 ,  C07D401/12 ,  C07D403/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04

Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

公开(公告)号：US20160039770A1

公开(公告)日：2016-02-11

申请号：US14821931

申请日：2015-08-10

Applicant: Genentech, Inc.

Inventor： Nicholas D. Smith ,  Mark R. Herbert

IPC: C07D231/56

CPC classification number: C07D231/56

Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.

Abstract translation: 本文描述的是雌激素受体调节剂（E）-3-（4 - （（E）-2-（2-氯-4-氟苯基）-1-（1H-吲唑-5-基） - 基）丁-1-烯-1-基）苯基）丙烯酸。 还描述了适用于给予包括雌激素受体调节剂的哺乳动物的药物组合物，以及使用雌激素受体调节剂单独使用并与其它化合物组合用于治疗与雌激素受体活性相关的疾病或病症的方法。

公开(公告)号：US09783503B2

公开(公告)日：2017-10-10

申请号：US14821931

申请日：2015-08-10

Applicant: Genentech, Inc.

Inventor： Nicholas D. Smith ,  Mark R. Herbert

IPC: C07D231/56

CPC classification number: C07D231/56

Abstract: Described herein are amorphous and crystalline forms of pharmaceutically acceptable salts of the estrogen receptor modulator (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl) phenyl)acrylic acid. Also described are pharmaceutical compositions suitable for administration to a mammal that include the estrogen receptor modulator, and methods of using the estrogen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with estrogen receptor activity.